Last updated: September 1, 2026
Tofersen, marketed by Biogen as Qalsody, is a precision therapy for adults with amyotrophic lateral sclerosis caused by mutations in the superoxide dismutase 1 gene, or SOD1-ALS. The drug received FDA accelerated approval in April 2023 based on reduction of plasma neurofilament light chain, a biomarker associated with neuronal injury. Its commercial opportunity is limited by the small SOD1-ALS population, while its price, intrathecal administration, diagnostic dependence, and uncertain clinical-outcome evidence constrain near-term adoption.
The commercial model is therefore built around high annual treatment value rather than large patient volume. Qalsody is unlikely to become a mass-market ALS product. Its strategic value is greater as a proof point for genetically defined neurodegenerative disease and antisense-oligonucleotide development.
What is tofersen and how does Qalsody work?
Tofersen is an antisense oligonucleotide designed to bind SOD1 messenger RNA and reduce production of SOD1 protein. Mutations in SOD1 account for roughly 1% to 2% of all ALS cases, although the proportion varies by population and testing method.
Qalsody is administered by lumbar puncture:
| Treatment phase |
Dose and schedule |
| Loading phase |
100 mg on Days 0, 14, and 28 |
| Maintenance phase |
100 mg every 28 days |
| Route |
Intrathecal injection |
| FDA status |
Accelerated approval, April 25, 2023 |
| Approved population |
Adults with SOD1 mutation-associated ALS |
The treatment requires genetic confirmation. This creates a diagnostic bottleneck because many ALS patients are not tested promptly for SOD1 mutations. Biogen and treatment centers must identify eligible patients, arrange genetic testing, coordinate repeated lumbar punctures, and manage administration capacity.
The FDA approval was based on biomarker evidence from the VALOR study and its open-label extension. VALOR did not meet its primary clinical endpoint at 28 weeks, but tofersen reduced plasma neurofilament light chain. The FDA required a post-approval confirmatory study to verify clinical benefit.[1]
How large is the tofersen market?
The addressable market is small but economically attractive per patient. The commercial population depends on four variables:
- The number of people living with ALS.
- The percentage with SOD1 mutations.
- The percentage who receive genetic testing.
- The percentage who begin and remain on treatment.
The United States has an estimated 25,000 to 30,000 people living with ALS at a given time. SOD1 mutations account for a small fraction of cases. The theoretical U.S. prevalent population eligible for Qalsody is therefore measured in hundreds rather than tens of thousands, although global prevalence and incident treatment can expand the pool.
The market is broader than the initial diagnosed population because genetic testing is increasing. Biogen’s commercial strategy depends on testing penetration, referral to specialized ALS centers, payer approval, and physician willingness to use a drug supported by accelerated approval and biomarker evidence.
Qalsody pricing and revenue potential
Biogen set Qalsody’s U.S. list price at approximately $163,500 per year at launch, according to contemporaneous industry reporting. Actual net price depends on rebates, government discounts, patient assistance, and payer agreements.[2]
A simplified revenue framework illustrates the economics:
| Treated U.S. patients |
Gross annual revenue at $163,500 per patient |
| 250 |
$40.9 million |
| 500 |
$81.8 million |
| 1,000 |
$163.5 million |
| 2,000 |
$327.0 million |
These figures are gross list-price calculations, not reported net sales. They exclude international pricing, discontinuation, reimbursement discounts, and treatment interruptions.
The commercial ceiling is constrained by the rarity of SOD1-ALS. Even strong penetration is unlikely to produce blockbuster-scale revenue unless the drug is expanded into additional SOD1-related conditions or the eligible population is materially larger than current estimates.
What is the financial trajectory for Qalsody?
Qalsody launched in the second quarter of 2023. Its first commercial year was a ramp-up period affected by:
- limited physician awareness;
- low baseline genetic-testing rates;
- reimbursement and prior-authorization requirements;
- the need for intrathecal administration;
- patient reluctance to undergo repeated lumbar punctures;
- uncertainty surrounding accelerated approval;
- the small number of specialized ALS treatment centers.
Biogen reports Qalsody within its product portfolio, but the product does not have the revenue scale of Spinraza, Tecfidera, or Leqembi. The key financial indicators are patient starts, persistence, geographic reimbursement, and the outcome of the confirmatory clinical program.
Qalsody’s economics are more favorable than its revenue scale suggests. The drug is manufactured as an oligonucleotide injectable, and the cost of goods is generally expected to be lower than the selling price. The commercial burden is concentrated in clinical development, genetic-testing support, specialist sales infrastructure, patient services, and medical education.
What could improve Qalsody revenue?
Revenue growth could come from:
- higher SOD1 genetic-testing rates;
- diagnosis earlier in the ALS disease course;
- wider reimbursement;
- adoption outside major academic centers;
- improved clinical evidence from longer-term follow-up;
- international launches;
- use in presymptomatic or early-stage mutation carriers, if supported by future data.
The most important variable is not price. It is the number of genetically confirmed patients who start treatment and remain on a monthly administration schedule.
What clinical evidence supports tofersen sales?
In VALOR, tofersen reduced plasma neurofilament light chain relative to placebo. The 28-week primary clinical endpoint did not show a statistically significant difference on the ALS Functional Rating Scale-Revised, respiratory function, or muscle strength measures.[1]
Longer-term open-label-extension data reported slower decline in several clinical measures among patients who began tofersen earlier. These findings support continued use but do not eliminate the evidentiary risk created by accelerated approval.
The commercial consequence is direct. Payers and physicians may treat Qalsody as disease-modifying therapy, but some may require evidence of functional benefit before broadening use. The confirmatory study is therefore a revenue event as well as a regulatory event.
When could tofersen lose exclusivity?
Qalsody’s exclusivity profile has several components:
| Exclusivity category |
Relevance |
| Orphan-drug exclusivity |
FDA orphan exclusivity generally runs for seven years from approval |
| New chemical entity exclusivity |
Not generally the primary protection for an antisense oligonucleotide already supported by prior development rights |
| Patent protection |
Depends on issued composition, sequence, formulation, manufacturing, and method-of-use patents |
| Pediatric exclusivity |
Could add six months if applicable and earned |
| Accelerated-approval status |
Does not itself create long-term market exclusivity |
The FDA orphan-drug exclusivity period is expected to run from April 2023 through April 2030, subject to the statutory framework and any applicable pediatric extension.[3] Patent expiry could extend beyond orphan exclusivity.
The precise loss-of-exclusivity date depends on issued patents, terminal disclaimers, patent-term adjustment, patent-term extension, and the scope of claims covering the marketed formulation and dosing regimen. A reliable launch analysis must distinguish between the expiry of a core composition patent and the expiry of later method-of-use or manufacturing patents.
What patents protect tofersen?
Tofersen is supported by an intellectual-property estate associated with Ionis Pharmaceuticals and its development and commercialization arrangements with Biogen. The relevant claim categories include:
- antisense sequences targeting human SOD1 RNA;
- treatment of SOD1 mutation-associated ALS;
- dosing schedules for intrathecal administration;
- pharmaceutical compositions;
- manufacturing and purification processes;
- use of neurofilament biomarkers to monitor treatment response.
The key legal question is whether a later entrant can design around the marketed antisense sequence while retaining sufficient SOD1 knockdown activity. Sequence-specific claims can create a meaningful barrier, but they may be narrower than broad small-molecule composition claims.
Qalsody is regulated as a drug under an FDA new drug application rather than as a traditional monoclonal-antibody biologic. Biosimilar substitution is therefore not the principal competitive pathway. A competing oligonucleotide would more likely require its own application and would face clinical, manufacturing, and intellectual-property barriers.
Public patent records should be reviewed by jurisdiction and claim family. The relevant diligence points are the earliest priority dates, issued claim scope, patent-term adjustment, continuation activity, and whether patents are listed in the FDA Orange Book. The FDA approval label identifies Qalsody under NDA 212994.[4]
What is the Orange Book status of Qalsody?
Qalsody’s regulatory protection is tied to an FDA-approved NDA. The Orange Book analysis should focus on whether Biogen or its licensors have listed patents covering:
- the tofersen active ingredient;
- the injectable formulation;
- the intrathecal dosing regimen;
- the approved SOD1-ALS method of use.
An Orange Book listing would permit a generic applicant to submit a Paragraph IV certification against the listed patent. The absence of a listed patent would not eliminate patent risk because unlisted patents can still support infringement litigation or other commercial enforcement strategies.
No established public record of a major Paragraph IV challenge to Qalsody was reported through the initial commercial period after approval. The small patient population reduces the immediate incentive for a conventional generic challenge, particularly where development requires a specialized intrathecal product and a narrow genetic indication.
Which companies are challenging tofersen?
No major commercial competitor had established an approved direct substitute for tofersen during the initial post-launch period. Competitive threats fall into four categories:
Competing SOD1 therapies
Ionis and Biogen hold the leading commercial position in SOD1-ALS through Qalsody. Other companies could pursue gene silencing, RNA interference, gene editing, viral-vector delivery, or alternative antisense approaches.
Broader ALS therapies
Qalsody competes indirectly with symptomatic and disease-modifying ALS products, including riluzole, edaravone, and their respective formulations. These drugs address broader ALS populations and do not require SOD1 mutation testing.
Gene therapy approaches
A one-time gene therapy could be commercially disruptive if it produces durable SOD1 suppression and avoids monthly intrathecal dosing. The development risk is high because ALS is heterogeneous and long-term neuronal recovery may be limited after irreversible damage.
Generic or follow-on oligonucleotides
A follow-on product would need to overcome sequence, formulation, delivery, manufacturing, regulatory, and clinical barriers. A simple small-molecule-style generic substitution is unlikely.
What generic entry risks exist for Qalsody?
Generic entry risk is low in the near term and rises after orphan exclusivity and core patent protections expire. The major barriers are:
- limited patient volume;
- the need for a specialized intrathecal delivery program;
- genetic eligibility requirements;
- high clinical-development costs relative to the addressable market;
- uncertain substitution rules for antisense oligonucleotides;
- possible patents covering sequence, use, formulation, and manufacturing.
The greatest competitive risk may come from a clinically superior SOD1 therapy rather than a conventional generic. A durable treatment administered less frequently could capture patients from Qalsody even before formal patent expiry.
How does tofersen compare with other ALS drugs?
| Product |
Company |
Target population |
Administration |
Market position |
| Qalsody, tofersen |
Biogen |
SOD1-mutation ALS |
Intrathecal, monthly maintenance |
Precision therapy |
| Spinraza, nusinersen |
Biogen |
Spinal muscular atrophy |
Intrathecal |
Established antisense franchise |
| Relyvrio, AMX0035 |
Amylyx |
Broad ALS population |
Oral/suspension |
Commercially withdrawn after negative confirmatory data |
| Radicava, edaravone |
Mitsubishi Tanabe |
Broad ALS population |
Intravenous or oral |
Symptom and progression-focused therapy |
| Riluzole |
Multiple manufacturers |
Broad ALS population |
Oral |
Low-cost standard therapy |
Spinraza gives Biogen experience with intrathecal antisense commercialization, payer engagement, specialty-center distribution, and patient support. Qalsody has a much smaller population but a more genetically targeted label.
What litigation and settlement issues affect tofersen?
No major public patent litigation or Paragraph IV settlement involving Qalsody was established during its initial launch period. The litigation risk is likely to remain limited while the eligible population is small and orphan exclusivity remains active.
Future disputes could involve:
- infringement of SOD1 antisense sequence claims;
- validity of continuation patents;
- enablement and written-description challenges;
- patent-term calculations;
- method-of-use claims for monthly intrathecal dosing;
- licensing rights between Ionis and Biogen.
Commercial agreements between Ionis and Biogen are central to economic ownership, development obligations, and royalty allocation. Ionis developed the antisense technology and has historically used licensing and collaboration structures with Biogen for neurological medicines.[5]
What is the FDA regulatory outlook for tofersen?
Qalsody remains exposed to the accelerated-approval framework. The confirmatory evidence must establish clinical benefit or the FDA could require labeling changes, impose additional restrictions, or pursue withdrawal under the accelerated-approval process.
The regulatory outlook has four commercial implications:
- Positive confirmatory evidence could expand physician confidence and payer coverage.
- Mixed evidence could preserve use but limit penetration.
- Negative evidence could materially reduce revenue.
- A successful outcome could support earlier genetic testing and broader use in SOD1-ALS.
The biomarker response is commercially useful, but clinical outcomes remain the decisive regulatory issue.
Key Takeaways
- Qalsody is the first FDA-approved therapy specifically directed at SOD1-mutation ALS.
- Its market is small, but annual treatment value is high.
- Revenue growth depends on genetic testing, specialist-center adoption, reimbursement, and treatment persistence.
- The FDA approval is accelerated and remains dependent on confirmatory clinical evidence.
- Orphan-drug exclusivity is expected to protect the product through approximately April 2030, subject to statutory extensions.
- Generic risk is limited in the near term because of the small population and intrathecal antisense complexity.
- The largest long-term threat is a more durable or less invasive SOD1 therapy, not a conventional generic.
- Patent diligence should focus on sequence, method-of-use, formulation, manufacturing, and continuation claims associated with Ionis and Biogen.
FAQs About Tofersen Commercialization and Exclusivity
Is tofersen a biologic or a generic drug?
Tofersen is an antisense oligonucleotide approved through an FDA new drug application. It is not a conventional small-molecule generic and is not expected to follow the standard biosimilar pathway used for monoclonal antibodies.
How often do patients receive Qalsody?
Patients receive three loading doses 14 days apart, followed by a 100 mg intrathecal maintenance dose every 28 days.
Does Qalsody treat all ALS patients?
No. The FDA indication is limited to adults with ALS caused by a mutation in the SOD1 gene.
Could a gene therapy replace tofersen?
Yes. A durable SOD1 gene-silencing or gene-editing therapy could compete directly if it demonstrates durable benefit and an acceptable safety profile.
What is the primary investment risk for Qalsody?
The primary risk is limited commercial scale combined with dependence on confirmatory clinical evidence. A negative regulatory outcome would affect adoption, reimbursement, and the product’s long-term revenue potential.
References
- U.S. Food and Drug Administration. (2023). FDA approves new treatment for adults with amyotrophic lateral sclerosis associated with a mutation in the SOD1 gene. https://www.fda.gov
- Biogen Inc. (2023). Qalsody prescribing information. https://www.qalsodyhcp.com
- U.S. Food and Drug Administration. (2023). Orphan-drug designation and exclusivity. https://www.fda.gov
- U.S. Food and Drug Administration. (2023). Qalsody NDA 212994 approval materials. https://www.accessdata.fda.gov
- Ionis Pharmaceuticals, Inc. (2023). Annual report on Form 10-K. https://ir.ionispharma.com
